RecruitingNCT02285582

International Rare Histiocytic Disorders Registry (IRHDR)


Sponsor

The Hospital for Sick Children

Enrollment

400 participants

Start Date

Oct 1, 2014

Study Type

OBSERVATIONAL

Conditions

Summary

The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that can be sometimes life-threatening. Since they are extremely rare, there is limited understanding of their causes and best treatment options. Physicians, patients and parents of children with RHDs frequently consult members of the Histiocyte Society regarding the best management of these disorders. Very often, no specific recommendation can be made due to the lack of prospective outcome data, or even large retrospective case series. The creation of an international rare histiocytic disorders registry (IRHDR) could facilitate a uniform diagnosis of the RHDs, as well as the collection and analysis of the clinical, epidemiological, treatment and survival data of patients with RHD. The registry may also lead to future therapeutic recommendations, provide a framework for future clinical trials and create excellent research opportunities.


Eligibility

Inclusion Criteria6

  • Any age at diagnosis.
  • Diagnosis of a rare histiocytic disorder, established before or after the opening of the registry.
  • Cases diagnosed from January - 01- 1995 until the present time and prospectively.
  • Signed informed consent by a patient, or parent/legal guardian.
  • Cognitively impaired patients can be included after consent by legal guardian/parent.
  • Deceased patients can be included if they are contacted at least 6 months after the death of their child and not on their child's birthday or anniversary of death.

Exclusion Criteria3

  • Informed consent has not been signed.
  • Diagnosis other than RHD.
  • Cases diagnosed before the year 1995.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRegistry study

No intervention.


Locations(15)

The University of Alabama at Birmingham

Birmingham, Alabama, United States

Children's Hospital of Los Angeles

Los Angeles, California, United States

Valley Children's Hospital

Madera, California, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Hospital Nacional de Pediatria Garrahan

Buenos Aires, Argentina

The Hospital for Sick Children

Toronto, Ontario, Canada

Centre hospitalier universitaire Sainte-Justine

Montreal, Quebec, Canada

University Hospital Brno

Brno, Czechia

Rostock University Medical Hospital

Rostock, Germany

Azienda Ospedaliero-Universitaria Meyer

Florence, Italy

Prinses Maxima Center

Utrecht, CS, Netherlands

Children's Memorial Health Institute

Warsaw, Poland

Hospital Universitario Cruces

Barakaldo, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02285582


Related Trials